Author Correction: The IL-33-PIN1-IRAK-M axis is critical for type 2 immunity in IL-33-induced allergic airway inflammation.
Saved in:
| Title: | Author Correction: The IL-33-PIN1-IRAK-M axis is critical for type 2 immunity in IL-33-induced allergic airway inflammation. |
|---|---|
| Authors: | Nechama M; Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA., Kwon J; Department of Molecular Biology & Genetics, Cornell University, Ithaca, NY, 14853, USA., Wei S; Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA., Tun-Kyi A; Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA., Welner RS; Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA., Ben-Dov IZ; Department of Nephrology and Hypertension, Hadassah-Hebrew Medical Center, 91120, Jerusalem, Israel., Arredouani MS; Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA., Asara JM; Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA., Chen CH; Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA., Tsai CY; Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA., Nelson KF; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA., Kobayashi KS; Department of Microbial Pathogenesis & Immunology, Texas A&M Health Science Center, College Station, TX, 77843, USA., Israel E; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA., Zhou XZ; Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA., Nicholson LK; Department of Molecular Biology & Genetics, Cornell University, Ithaca, NY, 14853, USA. lkn2@cornell.edu., Lu KP; Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA. klu@bidmc.harvard.edu.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA. klu@bidmc.harvard.edu.; Institute for Translational Medicine, Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Fujian Medical University, Fuzhou, 350108, Fujian, China. klu@bidmc.harvard.edu. |
| Source: | Nature communications [Nat Commun] 2023 Jun 19; Vol. 14 (1), pp. 3622. Date of Electronic Publication: 2023 Jun 19. |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE; PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-023-39297-5 |
